Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 May 17;405(10491):1743-1756.
doi: 10.1016/S0140-6736(25)00162-X. Epub 2025 May 1.

Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial

Affiliations
Free article
Randomized Controlled Trial

Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial

Jason Gardosi et al. Lancet. .
Free article

Abstract

Background: The benefits and harms of early induction of labour to reduce shoulder dystocia in fetuses suspected to be large for gestational age (LGA) are uncertain. We aimed to investigate whether early induction of labour is associated with a reduced risk of shoulder dystocia compared with standard care.

Methods: In this open-label, randomised controlled phase 3 trial, women aged ≥18 years with a suspected LGA fetus (estimated fetal weight >90th customised percentile) as identified by ultrasound scan between 35 weeks and 0 days (35+0 weeks) of gestation and 38+0 weeks' gestation, recruited from 106 hospitals across England, Scotland, and Wales in the UK, were randomly assigned (1:1) by web app to standard care or induction of labour between 38+0 weeks' gestation and 38+4 weeks' gestation using minimisation, balancing site, estimated fetal weight percentile (≤95th EFW percentile or >95th EFW percentile), and maternal age (≤35 years or >35 years). Key exclusion criteria included drug-treated diabetes, gestational diabetes, and elective caesarean section or induction already planned or indicated for any reason. Our primary outcome was incidence of shoulder dystocia, assessed by a masked independent expert adjudication panel who reviewed participants' delivery notes. Induction of labour was anticipated to result in birth 10·5 days earlier with a 300 g lower birthweight on average than standard care. We did an intention-to-treat (ITT) analysis in all participants for whom we had primary outcome data, and a per-protocol analysis in participants in the induction group who went into labour or were induced at 38+0 to 38+4 weeks' gestation versus participants in the standard care group who had not started labour, been induced, or had an elective caesarean section before 38+4 weeks' gestation. This study was registered with ISRCTN (18229892) and is no longer recruiting.

Findings: Between June 8, 2018, and Oct 25, 2022, 2893 women were randomly assigned to induction of labour (n=1447) or standard care (n=1446); the trial was terminated before the target of 4000 participants was reached on advice of the data monitoring committee following the lower-than-expected incidence of shoulder dystocia in the standard care group. Two participants in the induction group and seven in the standard care group had missing data for the primary outcome and were excluded from the ITT analysis. In the ITT analysis, 33 (2·3%) of 1445 babies in the induction group versus 44 (3·1%) of 1439 in the standard care group had shoulder dystocia (risk ratio [RR] 0·75 [95% CI 0·51-1·09]; p=0·14) with a mean difference of -6·0 days' (95% CI -6·3 to -5·6) gestation and -163·6 g (-190·0 to -137·1) birthweight between trial groups. 355 (24·6%) of 1446 mothers in the standard care group were induced, delivered, or went into labour at or before 38+4 weeks' gestation. In the per-protocol analysis, 27 (2·3%) of 1180 babies in the induction group versus 40 (3·7%) of 1074 in the standard care group had shoulder dystocia (RR 0·62 [0·41-0·92]; p=0·019), and there was a mean difference of -8·1 days' (-8·4 to -7·9) gestation and -213·3 g (-242·0 to -184·6) birthweight between trial groups. One neonatal death occurred from perinatal asphyxia after shoulder dystocia in the standard care group, and one neonatal death occurred following sepsis and congenital pneumonia in the induction group. 88 (6·1%) of 1447 mothers in the induction group had an adverse event versus 108 (7·5%) of 1446 in the standard care group (RR 0·81 [0·62 to 1·06]; p=0·13). Similar numbers of serious adverse events were reported in both groups.

Interpretation: No significant difference in incidence of shoulder dystocia was found between trial groups in the ITT analysis, probably due to the high proportion of earlier-than-expected deliveries in the standard care group reducing the intended between-group differences in gestational age and birthweight. However, in the per-protocol analysis, compared with all deliveries after 38+4 weeks' gestation, induction of labour between 38+0 weeks' gestation and 38+4 weeks' gestation did show a significant reduction in shoulder dystocia. This study provides pregnant women with suspected LGA fetuses and their clinicians important information about choices and decision making for timing and mode of birth.

Funding: National Institute for Health and Care Research Health Technology Assessment Programme.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests JG, EB, and HE work for the Perinatal Institute, a not-for-profit social enterprise which has developed the GROW customised growth chart and percentile calculator used in this study. DB has received grant funding from the UK National Institute for Health and Care Research (NIHR) and the UK Medical Research Council (MRC). She is the Editor in Chief of Midwifery journal and receives an honorarium for this role. She is also Chair of Trustees (unpaid) for the Mothers with Anal Sphincter Injuries in Childbirth Foundation. A-MS has received grants from the NIHR as chief investigator or co-investigator on multiple research projects. She is a member of the UK National Screening Committee and a member of the Resuscitation Council UK ReSPECT wider stakeholder group. MU is chief investigator or co-investigator on multiple previous and current research grants from the NIHR, and is a co-investigator on grants funded by the Australian National Health and Medical Research Council and Norwegian Medical Research Council. He was an NIHR Senior Investigator until March 2021. He is a director and shareholder of Clinvivo, which provides electronic data collection for health services research. He receives some salary support from University Hospitals Coventry and Warwickshire. He is a co-investigator on two current and one completed NIHR-funded studies that have, or have had, additional support from Stryker. He has accepted travel expenses from professional bodies for presenting at academic meetings. SQ is Chair of the Trial Steering Committee for the Mifepristone Outpatient Labour Induction study. HM is a member of the NIHR Health Technology Assessment General Funding Commissioning Committee. SP receives support as a UK NIHR Senior Investigator (NF-SI-0616-10103) and from the NIHR Applied Research Collaboration Oxford and Thames Valley. LJE, KB, GB, SD, JF, AG, RL, SN, and SW declare no competing interests.

Comment in

References

Publication types

LinkOut - more resources